[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"all-cause-mortality\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:all-cause-mortality":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,83,111,142,175,199],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":45,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100641995","human-observatory-study-100641995",false,"NCT07646782","Human Observatory Study","The Human Observatory: A Prospective Individual and Population-Level Study of Aging, Health, and Longevity","HOS","Inclusion Criteria:\n\n* Enrolled in the 100-Year Human Aging Study at any fixed or mobile clinical site; OR completion of online health screener with provision of geographic anchor data and consent.\n\nExclusion Criteria:\n\n* Age under 18 years (current protocol; pediatric amendment planned).",true,"ALL","18 Years",{"count":21,"type":22},1000000,"ESTIMATED","OBSERVATIONAL","The Human Observatory Study is a prospective observational and ecological surveillance study building a continuously-updating world model for human health, disease, and death at the individual and population level. Individual multi-system clinical data from enrolled participants are linked to a continuously-ingested ecological data infrastructure spanning environmental exposures, social determinants, genealogical and family history records, mortality data, and population health databases at geographic resolutions from home address to global scale and beyond. The resulting model generates individual screening recommendations informed by population-level causal estimates, and population-level causal forecasts anchored by present-timepoint individual clinical biology. Thus creating a feedback architecture designed to improve both simultaneously.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Aging","Mortality","All-cause Mortality","Life Expectancy","Cardiovascular Diseases","Neoplasms","Cognitive Dysfunction","Metabolic Syndrome","Frailty","Musculoskeletal Disease","Neurodegenerative Disease","Dementia","Activities of Daily Living","Health Related Quality of Life","Disability Physical","Environmental Exposure","Occupational Diseases","Health Equity","Social Determinants of Health",[46,47,48,49,50,51,52,53,54,55,56,57,58,43,59,60,61,62,63,64,65,66,67,68,69],"longevity","biological aging","causal inference","life expectancy","exposome","Environmental Health","Social Determinants","Genealogy","Family History","Human Family Tree","Population Health","Neighborhood Health","Geographic Health Disparities","Mortality Prediction","Biomarker Validation","Cardiopulmonary Exercise Testing","Body Composition","Preventive Medicine","Healthspan","Functional Decline","Centenarian","Space Medicine","Aerospace Medicine","World Model","RECRUITING","2026-06-09",{"date":73,"type":74},"2026-06-15","ACTUAL",{"date":76,"type":74},"2026-04-25",{"date":78,"type":22},"2099-12-31",{"name":80,"class":81},"Longevity Metrics, Inc.","INDUSTRY",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":91,"conditions":92,"keywords":98,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":110,"locationsCount":82},"100636291","100-year-human-aging-study-100636291","NCT07563777","100-Year Human Aging Study","100-Year Human Aging Study: Prospective Longitudinal Validation of Multi-System Health Measurements Against Mortality and Aging Outcomes","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up\n\nExclusion Criteria:\n\n* Age under 18 years",{"count":21,"type":22},"The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed and mobile clinical sites to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.",[26,93,94,27,33,30,32,95,31,34,38,96,40,97,37],"Aging Well","All-Cause Mortality","Musculoskeletal Diseases","Health-Related Quality of Life","Neuro-Degenerative Disease",[99,61,62,63,100,59,65,64,29,101,102,103,60,104,56,66],"Longevity","Surrogate Endpoint Validation","Biological Aging","Preventive Screening","Longitudinal Cohort","Human Performance",{"date":106,"type":74},"2026-06-11",{"date":108,"type":74},"2025-02-09",{"date":78,"type":22},{"name":80,"class":81},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":82},"100475124","the-global-cardiovascular-risk-consortium-100475124","NCT05466825","The Global Cardiovascular Risk Consortium","Predicting Cardiovascular Risk by Geographical Region and Sex Using Classical Cardiovascular Risk Factors","Inclusion Criteria:\n\nPopulation-based individual-level data with available information on the classical cardiovascular risk factors including body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes, as well as the outcomes of interest.\n\nExclusion Criteria:\n\n* Participants with age below 18 years\n* No information on the outcome of interest\n* No information on the exposure of interest (CVD risk factors)\n* History of CVD at baseline",{"count":119,"type":22},3000000,"The Global Cardiovascular Risk Consortium (GCVRC) brings together harmonized individual-level data from currently more than 2 million (anticipated: approximately 3 million) individuals across 133 cohorts, 40 countries, and 6 continents, with recruitment ongoing. The GCVRC examines the impact of classical cardiovascular risk factors-such as body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes-on cardiovascular disease (CVD) and death from any cause worldwide.",[28,122],"Cardiovascular Disease",[122,124,125,126,127,128,129,130,131],"Cardiovascular Risk Factors","Risk Factor Modification","Global","Lifetime Gain","Lifetime estimates","Projected risk reductions","Lifetime difference","Implementation strategies","2026-02-25",{"date":134,"type":74},"2026-02-27",{"date":136,"type":74},"2019-09-20",{"date":138,"type":22},"2028-06-30",{"name":140,"class":141},"Universitätsklinikum Hamburg-Eppendorf","OTHER",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":152,"phases":153,"briefSummary":155,"conditions":156,"keywords":163,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100579076","phase-3-prophylaxis-against-early-ventilator-associated-infections-in-acute-brain-injury-100579076","NCT06819592","PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury","PRophylaxis Against Early VENTilator-associated Infections to Reduce Mortality in Mechanically Ventilated Intensive Care Unit (ICU) Patients With Acute Brain Injuries: a Phase 3 Randomised, Double Blind, Parallel Group, Placebo-controlled Two-side Superiority Trial","PREVENT-NEURO","Inclusion Criteria:\n\n1. ≥ 18 years of age\n2. Receiving invasive mechanical ventilation\n3. The requirement for mechanical ventilation is because of an acute brain injury due to intracranial haemorrhage, ischaemic stroke, cerebral venous sinus thrombosis, subarachnoid haemorrhage, suspected hypoxic ischaemic encephalopathy post cardiac arrest, or traumatic brain injury.\n4. Admitted to an ICU or is anticipated to be admitted to an ICU\n\nExclusion Criteria:\n\n1. Endotracheal intubation was more than 12 hours ago\n2. Hospital admission was more than 72 hours ago\n3. Anticipated inability to deliver trial intervention within 90 minutes of randomisation\n4. Documented use of antibiotic therapy in the week prior to hospitalisation\n5. Currently receiving antibiotic therapy, or intention to prescribe antibiotic therapy, excluding cephazolin for peri-operative prophylaxis\n6. Any contraindication to receiving ceftriaxone\n7. Known or suspected pregnancy\n8. Death within 90 days is deemed inevitable due to the current illness or intercurrent medical conditions\n9. Previously enrolled in the PREVENT-NEURO trial.",{"count":151,"type":22},3300,"INTERVENTIONAL",[154],"PHASE3","This research is about whether treatment with a commonly used antibiotic can prevent infections in airway and lungs and improves the chance of surviving, if it is given soon after patients commence mechanical ventilation when they have been admitted to hospital with an acute severe brain injury.\n\nAn acute severe brain injury can occur as a result of a stroke, a traumatic injury or due to lack of oxygen to the brain that happens as a result of a cardiac arrest.\n\nPatients who are unconscious after an acute severe brain injury often need assistance to breath adequately, and this assistance is given by a breathing tube, connected to a mechanical ventilator. This treatment is an emergency medical treatment. The breathing tube is inserted into the patients' airway by either their mouth or neck. For patients who need assistance with their breathing from a mechanical ventilator, infections in the airways and lungs, known as pneumonia, are a common complication. Everyone naturally has bacteria in their mouth, esophagus and stomach. Clinicians think that during the process of inserting the breathing tube, small amounts of these bacteria can be introduced into the airways and lung when people are unconscious following an acute severe brain injury, or during the process of placing the breathing tube into the airways. These bacteria are now in a place they aren't meant to be and can cause an infections in the airways and lungs known as pneumonia.\n\nThe purpose of this research is to see if giving one dose of a common antibiotic can prevent patients developing pneumonia, which is associated with having a breathing tube inserted and being on a ventilator, improving the chance of recovery following the acute severe brain injury and ultimately improving the chance of surviving.\n\nWhen patients have a known infection, current guidelines are to treat them with antibiotics. Antibiotics work to kill the bacteria causing the infection. When a patient has an infection in their lungs, they often need to stay on the mechanical ventilator for longer. While current practice is to give patients with a proven infection in their airways and lungs (pneumonia) antibiotics, it is unknown if giving an antibiotic to patients to prevent these infections before they show signs of pneumonia may lead to better outcomes.",[28,157,158,159,160,161,162],"Quality of Life","Disability, Intellectual","Neurological Disorder","Acute Brain Injury","Ventilation, Mechanical","Intensive Care Medicine",[160,164],"Mechanical Ventilation","2026-02-16",{"date":167,"type":74},"2026-02-19",{"date":169,"type":74},"2025-10-30",{"date":171,"type":22},"2029-12",{"name":173,"class":141},"The George Institute",9,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":183,"conditions":184,"keywords":188,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":82},"100608742","sarcopenia-metabolic-diseases-and-integrated-aging-longitudinal-evaluation-smile-100608742","NCT07205510","Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)","Inclusion Criteria:\n\nAdults aged 18 and over\n\nExclusion Criteria:\n\n1. Does not cooperate in signing the informed consent form;\n2. Does not possess legal capacity;\n3. In a state of loss of consciousness;\n4. Suffering from severe mental illness, unable to communicate normally;\n5. The researcher believes that the subject has a disease that affects the assessment of results and is unsuitable for inclusion.",{"count":182,"type":22},10000,"This study aims to establish an ambispective cohort platform centered on the pathological axis of \"sarcopenia-metabolic disorders-aging progression\", integrating multimodal data including demographic characteristics, lifestyle factors, clinical phenotypes, laboratory tests, medical imaging, and biospecimens. Namely 'Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)'.",[185,186,28,26,187],"Sarcopenia","Metabolic Diseases","Cardiometabolic Diseases",[185,186,26,189,187],"All-cause mortality","2025-09-25",{"date":192,"type":74},"2025-10-03",{"date":194,"type":74},"2020-12-01",{"date":196,"type":22},"2040-12-31",{"name":198,"class":141},"RenJi Hospital",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":17,"sex":18,"minAge":207,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":152,"phases":210,"briefSummary":212,"conditions":213,"keywords":222,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":82},"100542080","advice-of-moderate-drinking-pattern-versus-advice-on-abstention-on-major-disease-and-mortality-100542080","NCT06338215","Advice of Moderate Drinking Pattern Versus Advice on Abstention on Major Disease and Mortality","A Non-inferiority Randomized Trial Testing an Advice of Moderate Drinking Pattern Versus Advice on Abstention on Major Disease and Mortality","UNATI","Inclusion Criteria:\n\n* Males aged 50-70 years, Women aged 55-75 years\n* Drinkers of any alcoholic beverage initially consuming 3 or more but 40 or less drinks\u002Fwk\n* Projected life expectancy more than 5 years (according to the judgment of their attending physician)\n* Willing to receive advice during up to 4 years on how to improve their alcohol intake making it healthier\n\nExclusion Criteria:\n\n1. Participants without smartphone or a computer (or tablet) with Internet connection.\n2. Drinkers of less than 30 g of pure alcohol\u002Fwk or more than 400 g of pure alcohol\u002Fwk\n3. Illiteracy, inability\u002Funwillingness to give written consent or communicate with study staff, or inadequate abilities for the use of on-line technologies\n4. Participants with any sever psychiatric condition or with a diagnosis of cognitive impairment or dementia.\n5. Participants with liver cirrhosis or prior liver cancer.\n6. Patients with a recent diagnosis of breast cancer (diagnosed in the last 10 years).\n7. Patients under habitual use of high-dose medications that completely preclude any use of alcohol. Most of these patients will be already excluded by the second or fourth exclusion criteria.","50 Years","75 Years",{"count":182,"type":22},[211],"NA","The goal of this clinical trial is to test two advices on alcohol drinking in more than 10.000 Spanish adult drinkers (men of 50 or more years and women of 55 or more years).\n\nThe main question it aims to answer is to test the non-inferiority advice of a moderate alcohol drinking pattern on all-cause mortality and other chronic disease like cardiovascular disease, cancer or type 2 diabetes.\n\nParticipants will receive during 4 years an advice to drink alcohol following a Mediterranean Alcohol Drinking Pattern (MADP): consuming alcohol in moderation, avoidance of binge drinking and preference for red wine.\n\nResearchers will compare those who will receive a MADP advice with those who will receive an advice on abstention to see if the advice on MADP is not inferior than the abstention advice to prevent all-cause mortality and other chronic diseases.",[214,30,215,216,217,218,37,219,220,221],"All Cause Mortality","Invasive Cancer","Liver Cirrhosis","Type 2 Diabetes","Depression","Injury Traumatic","Tuberculosis","Infections",[223,224,225,226,227,228,229],"Alcohol","Drinking Pattern","Abstention","Advice","Clinical Trial","Moderation","Mediterranean Alcohol Drinking Pattern","2024-12-11",{"date":232,"type":74},"2024-12-12",{"date":234,"type":74},"2024-05-15",{"date":236,"type":22},"2029-06-30",{"name":238,"class":141},"Clinica Universidad de Navarra, Universidad de Navarra"]